Effect of dexmedetomidine on mesenteric traction syndrome

Effect of dexmedetomidine on mesenteric traction syndrome during radical gastrectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014506

Enrollment

Unknown

Registered

2018-01-17

Start date

2018-02-01

Completion date

Unknown

Last updated

2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

radical gastrectomy

Interventions

Control:Saline

DEX1:0.5 µg/kg dexmedetomidine

DEX2:1.0 µg/kg dexmedetomidine

Eligibility

Sex/Gender

All

Age

No minimum to 65 Years

Inclusion criteria

Inclusion criteria: Patients with ASA I or II, aged =70 years, who were scheduled for elective radical gastrectomy

Exclusion criteria

Exclusion criteria: body mass index =28 kg/m2, preoperatively taking non-steroidal anti-inflammatory drugs, cardiovascular disease, hypertension with poor clinical control

Design outcomes

Primary

Measure	Time frame
concentration of plasma 6-keto-PGF1a;incidence rate of face flushing;incidence rate of hypotension;onset and duration of hypotension;dosage of phenylephrine;	—

Secondary

Measure	Time frame
BP and HR;concentrations of plasma norepinephrine and epinephrine;effective-site concentration of propofol and remifentanil;	—

Countries

China

Contacts

Public ContactZheng Chen

Affiliated People's Hospital of Jiangsu University

czczgljglj@163.com+86 18952819909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026